フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Company Announcement Daratumumab receives Fast Track designation in double refractory multiple myeloma Potential for expedited...
Company Announcement Arzerra(r) approved in Japan for relapsed / refractory CLL Genmab to receive DKK 20 million milestone payment...
COPENHAGEN, Denmark, March 7, 2013 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2012. Below is a summary...
Company Announcement Genmab sells manufacturing facility to Baxter Healthcare Corporation Genmab receives USD 10 million COPENHAGEN...
Company Announcement Arzerra worldwide net sales in Q4 2012 totaled GBP 14.5 million Full year 2012 Arzerra sales were GBP 60 million...
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark, Jan. 24, 2013 (GLOBE NEWSWIRE) -- Genmab A/S...
Company Announcement HexaBody platform is a novel technology platform to potently enhance antibody therapeutics Multiple new business...
Company Announcement Third pre-clinical milestone met in Lundbeck collaboration [Eur]1 million milestone payment to Genmab...
Company Announcement Genmab reaches key milestone in DuoBody® platform collaboration with Janssen $2 million milestone payment to...
Company Announcement Preliminary safety and efficacy data from final patients in part 1 of study continue to be encouraging Data...
Company Announcement - DuoBody® research collaboration with Kyowa Hakko Kirin - Genmab's fourth DuoBody technology collaboration COPENHAGEN...
COPENHAGEN, Denmark, Nov. 7, 2012 (GLOBE NEWSWIRE) -- Interim Report for the 9 Months Ended September 30, 2012 Company...
Company Announcement - Arzerra worldwide net sales in Q3 2012 totaled GBP 18.2 million - Genmab expects royalty payment of DKK 34 million...
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Genmab A/S...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約